Ignet

Gene Information

Gene symbol: PAX2

Gene name: paired box 2

HGNC ID: 8616

Related Genes

#	Gene Symbol	Number of hits
1	WT1	1 hits

Related Sentences

#	PMID	Sentence
1	9916932	WT1 and PAX-2 podocyte expression in Denys-Drash syndrome and isolated diffuse mesangial sclerosis.
2	9916932	One target gene of WT1 is PAX2, the expression of which is down-regulated in podocytes during early stages of nephrogenesis.
3	9916932	We demonstrate that WT1 mislocalization is associated with abnormal podocyte expression of PAX2 protein and RNA.
4	9916932	We suggest that persistent expression of PAX2 is likely to result from the loss of WT1 dependent transcriptional repression and may participate in the pathological mechanisms leading to glomerular dysfunction.
5	9916932	Abnormal distribution of WT1 and PAX2 was also observed in isolated diffuse mesangial sclerosis suggesting that a defect in WT1 could also be operative in isolated diffuse mesangial sclerosis.
6	9916932	WT1 and PAX-2 podocyte expression in Denys-Drash syndrome and isolated diffuse mesangial sclerosis.
7	9916932	One target gene of WT1 is PAX2, the expression of which is down-regulated in podocytes during early stages of nephrogenesis.
8	9916932	We demonstrate that WT1 mislocalization is associated with abnormal podocyte expression of PAX2 protein and RNA.
9	9916932	We suggest that persistent expression of PAX2 is likely to result from the loss of WT1 dependent transcriptional repression and may participate in the pathological mechanisms leading to glomerular dysfunction.
10	9916932	Abnormal distribution of WT1 and PAX2 was also observed in isolated diffuse mesangial sclerosis suggesting that a defect in WT1 could also be operative in isolated diffuse mesangial sclerosis.
11	9916932	WT1 and PAX-2 podocyte expression in Denys-Drash syndrome and isolated diffuse mesangial sclerosis.
12	9916932	One target gene of WT1 is PAX2, the expression of which is down-regulated in podocytes during early stages of nephrogenesis.
13	9916932	We demonstrate that WT1 mislocalization is associated with abnormal podocyte expression of PAX2 protein and RNA.
14	9916932	We suggest that persistent expression of PAX2 is likely to result from the loss of WT1 dependent transcriptional repression and may participate in the pathological mechanisms leading to glomerular dysfunction.
15	9916932	Abnormal distribution of WT1 and PAX2 was also observed in isolated diffuse mesangial sclerosis suggesting that a defect in WT1 could also be operative in isolated diffuse mesangial sclerosis.
16	9916932	WT1 and PAX-2 podocyte expression in Denys-Drash syndrome and isolated diffuse mesangial sclerosis.
17	9916932	One target gene of WT1 is PAX2, the expression of which is down-regulated in podocytes during early stages of nephrogenesis.
18	9916932	We demonstrate that WT1 mislocalization is associated with abnormal podocyte expression of PAX2 protein and RNA.
19	9916932	We suggest that persistent expression of PAX2 is likely to result from the loss of WT1 dependent transcriptional repression and may participate in the pathological mechanisms leading to glomerular dysfunction.
20	9916932	Abnormal distribution of WT1 and PAX2 was also observed in isolated diffuse mesangial sclerosis suggesting that a defect in WT1 could also be operative in isolated diffuse mesangial sclerosis.
21	9916932	WT1 and PAX-2 podocyte expression in Denys-Drash syndrome and isolated diffuse mesangial sclerosis.
22	9916932	One target gene of WT1 is PAX2, the expression of which is down-regulated in podocytes during early stages of nephrogenesis.
23	9916932	We demonstrate that WT1 mislocalization is associated with abnormal podocyte expression of PAX2 protein and RNA.
24	9916932	We suggest that persistent expression of PAX2 is likely to result from the loss of WT1 dependent transcriptional repression and may participate in the pathological mechanisms leading to glomerular dysfunction.
25	9916932	Abnormal distribution of WT1 and PAX2 was also observed in isolated diffuse mesangial sclerosis suggesting that a defect in WT1 could also be operative in isolated diffuse mesangial sclerosis.